|Medtronic IN.PACT Admiral Drug-Coated Balloon Demonstrates Consistent Results in Asia and Belgium According to New Data Presented at LINC 2017|
First Presentation of Results from Regional Cohorts of IN.PACT Global Study Reinforce Strong, Consistent and Safe Outcomes for PAD Patients
DUBLIN and LEIPZIG, Germany - Jan. 25, 2017 - Medtronic today presented new data at the Leipzig Interventional Course (LINC) 2017 conference supporting the IN.PACT® Admiral® drug-coated balloon (DCB) in patients with peripheral arterial disease (PAD). The real-world outcomes from regional cohorts of the IN.PACT Global Study in Asia and Belgium reinforce the strong efficacy and consistent outcomes of the IN.PACT Admiral DCB across multiple patient populations.
IN.PACT Global Study: Asian Subset
In this subset analysis, the low clinically-driven target lesion revascularization (CD-TLR) at one year (3.8 percent) was consistent with the results in the complete cohort of 1,406 patients in the IN.PACT Global Study (7.5 percent). Results of the primary safety endpoint in the Asian cohort were also consistent with results from the full Global Study cohort, with 96.2 percent of patients achieving positive outcomes.
IN.PACT Global Study: Belgium
In this patient subset, the low CD-TLR at one year (7.6 percent) was also consistent with the results in the complete cohort of patients in the IN.PACT Global Study (7.5 percent). Results of the primary safety endpoint in the Belgium cohort were also consistent with results from the full study, with 90.6 percent of patients achieving positive outcomes.
"The results from these two patient cohorts in Asia and Belgium support the unparalleled clinical evidence demonstrating the consistency, durability, and safety of the IN.PACT Admiral DCB," said Mark Pacyna, general manager of the Peripheral business, which is part of the Aortic & Peripheral Vascular division at Medtronic. "We continue to invest in the IN.PACT clinical program to provide clinicians the broadest possible set of outcomes and measures of clinical rigor among multiple patient populations. We are pleased to present these data and further the body of clinical evidence supporting IN.PACT Admiral as a frontline treatment option globally."
About IN.PACT Global Study
About IN.PACT Admiral Drug-Coated Balloon
To date, more than 200,000 patients have been treated with IN.PACT Admiral DCB.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.